Drug Trial Radar · NCT07567014
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
May 31, 2028
Study completion May 31, 2029
Sponsor
- Lead sponsor
- NYU Langone HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate emapalumab as a prophylactic therapy in preventing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients with hematologic malignancies receiving bispecific antibodies (BsAbs) as outpatient. The primary objectives of this study are to evaluate the efficacy, safety, and feasibility of prophylaxis with the interferon gamma (IFN-У -γ) inhibitor Emapalumab in preventing CRS and/or ICANS in patients receiving bispecific antibody therapy for hematologic malignancies.
Conditions
- Multiple Myeloma
- Large B-cell Lymphoma (LBCL)
Interventions
EmapalumabDrug
1.0 mg/kg IV one day prior to bispecific antibody therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with cytokine release syndrome (CRS) (grades 2-5, as per ASTCT criteria) and/or immune effector cell-associated neurotoxicity syndrome (ICANS) (grades 2-5, per ASTCT criteria) within 30 days of bispecific antibody administration.Time frame: Within 30 days of treatment
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
NYU Langone Health Perlmutter Cancer Center - Sunset Park
Brooklyn, New York
NYU Langone Health Perlmutter Cancer Center - Manhattan
Manhattan, New York
NYU Langone Health - Long Island
Mineola, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.